Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 06 January 2017 | By Michael Mezher
The Danish Medicines Agency has suspended Danish parallel importer Europharma DK's manufacturing authorisation and good manufacturing practice (GMP) certificate over "serious breaches of compliance" uncovered during an inspection of the company's Esbjerg, Denmark site last month.
According to Europharma DK's website, the company specializes in parallel import of drugs from other EU countries that it repackages and distributes in Denmark, Germany and Sweden.
However, the agency says it found Europharma DK's packaging operations to be out of compliance and that the company attempted to hide information from inspectors.
"Serious breaches of compliance with GMP, for example, [include] deliberately hidden information, deliberate action to avoid our control, falsification of the expiry date on medical product, use of a contract acceptor without audit of the site," the Danish Medicines Agency writes.
As a result of the inspection, the Danish Medicines Agency says it has suspended Europharma DK's manufacturing authorisation and withdrawn its GMP certificate.
"As from today, Europharma DK ApS must no longer perform manufacturing activities, including the purchase of medicinal products from other markets with the purpose of repackaging," the Danish Medicines Agency said in a press release on Tuesday, noting that the company will be prohibited from distributing or releasing any of their stored products.
However, the Danish Medicines Agency says it consulted with Europharma DK before issuing the suspension and says it expects the suspension will be temporary until the company is able to demonstrate compliance during a future inspection.
According to the Danish Medicines Agency, the issues cited during the inspection "do not generally affect the quality of [Europharma DK's] products," though some specific unnamed drugs "have been withdrawn from pharmacies."
Focus has reached out to the Danish Medicines Agency for clarification on what products have been subject to withdrawal.
EudraGMDP, Danish Medicines Agency
Tags: Danish Medicines Agency, Europharma DK
Regulatory Focus newsletters
All the biggest regulatory news and happenings.